^
    almost3years
    Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Royal Marsden NHS Foundation Trust | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Compound 451238
    over3years
    Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Royal Marsden NHS Foundation Trust | Active, not recruiting --> Recruiting | Trial completion date: Feb 2022 --> Jan 2023 | Trial primary completion date: Sep 2020 --> May 2022
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Compound 451238
    over4years
    Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Royal Marsden NHS Foundation Trust | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2020 --> Sep 2020
    Enrollment closed • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Compound 451238